

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
13180.18

In Re Application Of: ROULEAU et al.

JUN 1 2 2001

Serial No.
09/718,355

Filing Date
11/24/2000

Examiner

Group Art Unit
1645

Title:

**LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME
TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY**

RECEIVED

Address to:
Assistant Commissioner for Patents
Washington, D.C. 20231

JUN 1 3 2001
TECH CENTER 1600/2900

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application; within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or before the mailing date of a first Office Action on the merits, whichever event occurs last.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after three months of the filing of a national application, or the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; or after the mailing date of a first Office Action on the merits, whichever occurred last but before the mailing date of either:

1. a Final Action under 37 CFR 1.113, or
2. a Notice of Allowance under 37 CFR 1.311,

whichever occurs first.

Also submitted herewith is:

- ☐ a certification as specified in 37 CFR 1.97(e);

OR

- ☐ the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under 37 CFR 1.97(c).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.

13180.18

In Re Application Of: ROULEAU et al.

Serial No.

09/718,355

Filing Date

11/24/2000

Examiner

Group Art Unit

1645

Title:

**LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME
TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 07-1742 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

***This certificate may only be used if paying by deposit account.**

Signature

Alain M. LECLERC, Reg. No. 37036

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

Dated: **June 11, 2001**

CC:

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
13180.18

In Re Application Of: ROULEAU et al.



Serial No.
09/718,355

Filing Date
11/24/2000

Examiner

Group Art Unit
1645

Title:

**LOCI FOR IDIOPATHIC GENERALIZED EPILEPSY, MUTATIONS THEREOF AND METHOD USING SAME
TO ASSESS, DIAGNOSE, PROGNOSIS OR TREAT EPILEPSY**

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Assistant Commissioner is hereby authorized to charge and credit Deposit Account No. 07-1742 as described below. A duplicate copy of this sheet is enclosed.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

on _____
(Date)

Signature

Typed or Printed Name of Person Signing Certificate

*This certificate may only be used if paying by deposit account.

Certificate of Mailing by First Class Mail

I certify that this document and fee is being deposited on _____ with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Typed or Printed Name of Person Mailing Correspondence

Dated: June 11, 2001


Signature

Alain M. LECLERC, Reg. No. 37036

CC:

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
		5,223,409		Ladner et al.			

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	✓	Anderman, E. 1982, Genetic Basis of the Epilepsies, Raven Press, New York: 355-374.	✓
	~	Anderson et al. 1984, In Vitro 20(11): 856-8.	✓


EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

- | | |
|----|--|
| 3 | Annegers et al. 1982, Genetic Basis of the Epilepsies, Raven Press, New York: 151-9. ✓ |
| R | Baker et al. 1995, Cell Prolif. 28: 1-15. ✓ |
| 5 | Barker et al. 1984, Neurosci. Lett. 47: 313-8. ✓ |
| b | Bar-Sagi et al. 1985, J. Biol. Chem. 260(8): 4740-4. ✓ |
| 1 | Baunoch et al. 1992, Biotechniques 12(3): 412-7. ✓ |
| 6 | Berkovic et al. 1998, Ann. Neurol. 43: 435-45. ✓ |
| 9 | Biervert et al. 1998, Science 279: 403-6. ✓ |
| 10 | Bu et al. 1994, Genomics 21: 222-8. ✓ |
| 11 | Carell et al. 1994, Angew. Chem. Int. Ed. Engl. 33(20): 2061-63. |
| 12 | Charlier et al. 1998, Nat. Genet. 18(1): 53-5. |
| 13 | Chevion et al. 1996, Cell Prolif. 29: 437-46. |
| 14 | Chia et al. 1998, Exp. Cell Res. 244: 340-8. |

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)




Docket Number (Optional) CG/13180.18	Application Number 09/718,355
Applicant(s) ROULEAU, Guy A.	
Filing Date November 24, 2000	Group Art Unit 1645

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
	Cho et al. 1993, Science <u>261</u> : 1303-5. ✓
15	
	Clare et al. 2000, Drug Discov. Today <u>5</u> (11): 506-20. ✓
16	
	Commission on Classification and Terminology of the International League Against Epilepsy 1989, Epilepsia <u>30</u> (4): 389-99. ✓
17	
	Corey et al. 1991, Neurology <u>41</u> : 1433-6. ✓
18	
	Cull et al. 1992, Proc. Natl. Acad. Sci. USA <u>89</u> : 1865-9. ✓
19	
	Denyer et al. 1998, Drug Discovery Today <u>3</u> : 323-32. ✓
20	
	DeWitt et al. 1993, Proc. Natl. Acad. Sci. USA <u>90</u> : 6909-13. ✓
21	
	Elliott et al. 1999, Oncogene <u>18</u> : 3564-73. ✓
22	
	Elmslie et al. 1997, Hum. Mol. Genet. <u>6</u> (8): 1329-34. ✓
23	
	Engel et al. 1997, Epilepsy: A Comprehensive Textbook, Lippincott-Raven, Philadelphia: 1-7 (1). ✓
24	
	Erb et al. 1994, Proc. Natl. Acad. Sci. USA <u>91</u> : 11422-6. ✓
25	
	Escayg et al. 2000, Nat. Genet. <u>24</u> (4): 343-5.
26	
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)
CG/13180.18

Application Number
09/718,355

Applicant(s)
ROULEAU, Guy A.

Filing Date
November 24, 2000


Group Art Unit
1645

*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
28	Fodor et al. 1993, Nature <u>364</u> : 553-6. ✓
28	Gallop et al. 1994, J. Med. Chem. <u>37</u> (9): 1233-51. ✓
29	Gonzalez et al. 1998, Cellular and Molecular Biology <u>44</u> (7): 1117-27. ✓
30	Gonzalez et al. 1999, Drug Discovery Today <u>4</u> (9): 431-9. ✓
31	Greenberg et al. 1988, Am. J. Med. Genet. <u>31</u> : 185-92. ✓
22	Guipponi et al. 1997, Hum. Mol. Genet. <u>6</u> : 473-7. ✓
31	Gyapay et al. 1994, Nat. Genet. <u>7</u> : 246-9. ✓
34	Hamill et al. 1981, Pflügers Archiv. <u>391</u> : 85-100. ✓
35	Hu et al. 1999, The Journal of Pharmacology and Experimental Therapeutics <u>290</u> (1): 28-37. ✓
36	Kawai et al. 1999, Oncogene <u>18</u> : 3471-80. ✓
37	Komada et al. 1999, Genes & Dev. <u>13</u> : 1475-85. ✓
38	Lam, K.S. 1997, Anti-Cancer Drug Design <u>12</u> : 145-67. ✓
EXAMINER	DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Lam et al. 1991, Nature (354): 82-84. ✓

Lathrop et al. 1984, Am. J. Genet., 36: 460-5. ✓

Lennox et al. 1960, Epilepsy and related disorders, Little Brown: 532-74. ✓

Leppert et al. 1989, Nature 337: 647-8. ✓

Lewis et al. 1993, Am. J. Hum. Genet. 53: 670-5. ✓

Liu, L. 1999, Cell. Signal. 11(5): 317-24.

McConnell et al. 1992, Science 257: 1906-12. ✓

McPhee et al. 1998, J. Biol. Chem. 273(2): 1121-9. ✓

Miyaji-Yamaguchi et al. 1999, Journal of Molecular Biology 290: 547-57.

Morvan et al. 1986, Nucleic Acids Research, 14(12): 5019-35. ✓

Muir et al. 2000, Cerebrovascular Diseases 10: 431-6. ✓

Nakashima et al. 1999, J. Bone Joint Surg. Am. 81(5): 603-15. ✓


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Nielsen, P.E. 1999, Curr. Opin. Biotechnol. 10: 71-5.

51

Okuwaki et al. 1998, J. Biol. Chem. 273(51): 34511-8.

52

Ottman et al. 1989, Epilepsia 30(2): 157-61.

53

Ottman et al. 1995, Nat. Genet. 10: 56-60.

54

Ottman et al. 1997, Am. J. Hum. Genet. 60: 667-75.

55

Pugsley et al. 1998, Eur. J. Pharmacol. 342: 93-104.

56

Schroeder et al. 1998, Nature 396: 687-90.

57

Scott et al. 1990, Science 249: 386-90.

58

Silampää et al. 1991, Acta Neurol. Scand. 84: 523

59

Singh et al. 1998, Nat. Genet. 18(1): 25-9.

60

Sjolander et al. 1991, Anal. Chem. 63: 2338-45.

61

Steinlein et al. 1995, Nat. Genet. 11: 201-3.

62


EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)



Docket Number (Optional)

CG/13180.18

Application Number

09/718,355

Applicant(s)

ROULEAU, Guy A.

Filing Date

November 24, 2000

Group Art Unit

1645

*EXAMINER
INITIAL

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Szabo et al. 1995, Curr. Opin. Mol. Biol. 5: 699-705.

63

Tamaskovic et al. 1999, Biological Chemistry 380: 569-78.

64

Taylor et al. 1997, Adv. Pharmacol. 39: 47-98.

65

Wallace et al. 1998, Nature Genet. 19: 366-70.

66

Zuchermann et al. 1994, J. Med. Chem. 37(17): 2678-85.

67

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.